While anti‐inflammatory therapies targeting pathways such as IL‐1β and IL‐6 have shown promise in established atherosclerotic cardiovascular disease (ASCVD), potential systemic effects raise concerns about immune suppression and infection, underscoring the need for more precise immunomodulatory approaches. The gene discussed is IL6; the disease is infection.